Intradigm Licenses siRNA IP from UMass Medical School | GenomeWeb
NEW YORK (GenomeWeb News) – Intradigm has licensed siRNA technology from the University of Massachusetts Medical School that will help in its RNAi-based therapeutics programs, the company said today.
The UMass intellectual property covers “certain efficacy-enhancing structural elements” of siRNA, as well as parameters for structural modifications that will help the company “significantly improve the potency and efficacy of RNAi therapeutics,” Intradigm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.